Want to see JP:4894 full AI Analyst Report?
Top Page
Cuorips Inc.
(4894)
Select Model
Select Model
Rating:55Neutral
Price Target:
¥5,627.00
▼(-9.68% Downside)
Action:Reiterated
Date:08/26/26
The score is held back primarily by weak financial performance (declining revenue, widening losses, and worsening cash burn), partially offset by a strong, low-risk balance sheet with zero debt. Technicals are supportive with price above key moving averages and positive MACD, but valuation remains challenged due to negative earnings and no stated dividend.
Positive Factors
Zero Debt
A debt-free capital structure limits interest obligations and refinancing risk. This gives Cuorips greater flexibility to fund research, operations, and commercialization efforts without the additional pressure of debt servicing.
Negative Factors
Revenue Decline
The latest revenue contraction weakens evidence of product adoption and commercial traction. If the decline persists, Cuorips may struggle to spread fixed costs across sales and could require additional funding before reaching sustainable scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero Debt
A debt-free capital structure limits interest obligations and refinancing risk. This gives Cuorips greater flexibility to fund research, operations, and commercialization efforts without the additional pressure of debt servicing.
Read all positive factors
Cuorips Inc. (4894) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥45.35B
Dividend YieldN/A
Average Volume (3M)107.56K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth-50.60%
EPS Growth-70.48%
CountryJP
Employees51
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-124.55
Shares Outstanding8,276,716
10 Day Avg. Volume98,200
30 Day Avg. Volume107,556
Financial Highlights & Ratios
PEG Ratio-1.03
Price to Book (P/B)12.12
Price to Sales (P/S)271.07
P/FCF Ratio-52.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cuorips Inc. Business Overview & Revenue Model
Company Description
Cuorips Inc. specializes in the comprehensive lifecycle of iPS cell-derived cardiomyocyte sheets, undertaking their research, development, production, commercialization, and distribution. The firm's portfolio extends to include cellular, tissue-ba...
Cuorips Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 212.33M | 175.21M | 23.10M | 38.28M | 13.91M |
| Gross Profit | 45.90M | 91.56M | -60.47M | -57.64M | -82.09M |
| EBITDA | -996.81M | -513.57M | -518.38M | -371.78M | -280.46M |
| Net Income | -1.02B | -644.34M | -632.18M | -452.08M | -375.34M |
Balance Sheet | |||||
| Total Assets | 5.12B | 5.74B | 6.18B | 3.59B | 4.04B |
| Cash, Cash Equivalents and Short-Term Investments | 3.90B | 4.79B | 5.58B | 2.94B | 3.34B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 353.83M | 211.91M | 200.96M | 133.79M | 149.36M |
| Stockholders Equity | 4.75B | 5.53B | 5.98B | 3.45B | 3.90B |
Cash Flow | |||||
| Free Cash Flow | -1.10B | -892.81M | -474.83M | -412.18M | -249.45M |
| Operating Cash Flow | -1.06B | -812.62M | -451.06M | -401.61M | -220.76M |
| Investing Cash Flow | -7.59M | -117.99M | -33.50M | -8.97M | -28.44M |
| Financing Cash Flow | 176.84M | 143.11M | 3.12B | 10.69M | 48.54M |
Cuorips Inc. Technical Analysis
Positive
6230.00
Price Trends
4642.10
Positive
5242.55
Positive
6191.07
Negative
Market Momentum
251.98
Negative
66.59
Neutral
81.25
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4894, the sentiment is Positive. The current price of 6230 is above the 20-day moving average (MA) of 5097.50, above the 50-day MA of 4642.10, and above the 200-day MA of 6191.07, indicating a neutral trend. The MACD of 251.98 indicates Negative momentum. The RSI at 66.59 is Neutral, neither overbought nor oversold. The STOCH value of 81.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4894.
Cuorips Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ¥45.35B | -42.21 | ― | ― | -50.60% | -70.48% | |
54 Neutral | ¥35.25B | -78.23 | ― | ― | 3.43% | -53.59% | |
51 Neutral | ¥22.00B | -11.71 | ― | ― | ― | 6.10% | |
47 Neutral | ¥38.07B | 58.06 | ― | ― | -47.32% | ― | |
45 Neutral | ¥15.05B | -32.46 | ― | ― | -18.71% | -246.54% | |
42 Neutral | ¥9.23B | -7.98 | ― | ― | -56.16% | 3.12% |
* General Sector Average
JP:4894
Cuorips Inc.
5,840.00
-1,740.00
-22.96%
JP:4593
Healios KK
288.00
-252.00
-46.67%
JP:4599
StemRIM Inc.
351.00
46.00
15.08%
JP:4978
ReproCELL Inc.
149.00
-32.00
-17.68%
JP:7774
Japan Tissue Engineering Co., Ltd.
848.00
354.00
71.66%
JP:7776
CellSeed Inc.
231.00
-213.00
-47.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.